Treatment after JAK Inhibitor in Patients with Rheumatoid Arthritis – What to do Next?
Is it advisable to switch from one JAK inhibitor (JAKi) to another in patients with rheumatoid arthritis (RA)? What is the effectiveness of cycling JAKi of different classes compared with switching to a biological disease-modifying antirheumatic drug (bDMARD) in patients with RA after failure to the first JAKi?
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
